Patents Represented by Attorney, Agent or Law Firm Giulio A. DeConti
-
Patent number: 7357915Abstract: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described.Type: GrantFiled: August 2, 2002Date of Patent: April 15, 2008Assignees: The Board of Trustees of the Leland Stanford Junior University, University of WashingtonInventors: Francis G. Blankenberg, H. W. Strauss, Jonathan F. Tait, Peter D. Katsikis
-
Patent number: 6835710Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.Type: GrantFiled: August 3, 2000Date of Patent: December 28, 2004Assignees: HSC Research & Development Limited Partnership, Ontario Cancer InstituteInventors: Clifford A. Lingwood, Hannah Farkas-Himsley, Richard Hill
-
Patent number: 6831066Abstract: Compounds that modulate natural &bgr; amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a &bgr; amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a &bgr; amyloid peptide, preferably a retro-inverso isomer of A&bgr;17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group.Type: GrantFiled: March 24, 2003Date of Patent: December 14, 2004Assignee: Praecis Pharmaceuticals IncorporatedInventors: Mark A. Findeis, Kathryn Phillips
-
Patent number: 6831065Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-&kgr;B-dependent target gene expression in a cell.Type: GrantFiled: May 2, 2001Date of Patent: December 14, 2004Assignee: Yale UniversityInventors: Michael J. May, Sankar Ghosh
-
Patent number: 6825037Abstract: Recombinant transferrin, non-glycosylated recombinant transferrin, transferrin half-molecules and mutant transferrins having altered metal-binding or other properties are described. The recombinant transferrin molecules are expressed in functional form by stable eukaryotic cell lines such as baby hamster kidney cells transformed with an expression vector encoding the recombinant molecule. The recombinant transferrins can be used in metal chelation therapy to bind and clear excess toxic metals in patients suffering from metal overloads or as tissue culture medium supplements or replacements.Type: GrantFiled: November 15, 1999Date of Patent: November 30, 2004Assignees: University of Vermont, University of British ColumbiaInventors: Walter D. Funk, Ross T.A. MacGillivray, Anne B. Mason, Robert C. Woodworth
-
Patent number: 6821779Abstract: The instant methods pertain to improved methods for storing neural cells, preferably dissociated neural cells, prior to their use in transplantation and to the cells obtained using such methods. One embodiment pertains to methods for storing the neural cells in medium lacking added buffer or added protein, other embodiments feature neural cells which are maintained at 4° C. prior to cryopreservation and have comparable viability and/or functionality to freshly harvest cells. In addition, methods for storing and/or transplantation of porcine neural cells are described.Type: GrantFiled: August 17, 2001Date of Patent: November 23, 2004Assignees: University Hospital Groningen, Inc., Diacrin, Inc.Inventors: Jan Koopmans, Douglas B. Jacoby, Jonathan Dinsmore
-
Patent number: 6818669Abstract: A method and compositions are provided for increased cerebral bioavailability of blood-born compositions by administering the composition of interest while increasing brain NO levels. This increase in NO levels may be accomplished by stimulating increased production of NO by eNOS, especially by administering L-arginine, by administering agents that increase NO levels independent of ecNOS, or by any combination of these methods. As NO is increased, cerebral blood flow is consequently increased, and drugs in the blood stream are carried along with the increased flow into brain tissue. By increased flow, the site of action will be exposed to more drug molecules. By stimulating increased NO production, administration of drugs that are not easily introduced to the brain may be facilitated and/or the serum concentration necessary to achieve desired physiologic effects may be reduced.Type: GrantFiled: September 19, 2001Date of Patent: November 16, 2004Assignee: Enos Pharmaceuticals, Inc.Inventors: Michael A. Moskowitz, James K. Liao, Eyal S. Ron, Mary Nallin Omstead
-
Patent number: 6783756Abstract: A method for regulating expression of a tet operator-linked gene in a cell of a subject is disclosed. In one embodiment, the method involves introducing into the cell a nucleic acid molecule encoding a tetracycline-controllable transactivator (tTA), the tTA comprising a Tet repressor operably linked to a polypeptide which directly or indirectly activates transcription in eucaryotic cells; and modulating the concentration of a tetracycline, or analogue thereof, in the subject. Alternatively, in another embodiment, the method involves obtaining the cell from the subject, introducing into the cell a first nucleic acid molecule which operatively links a gene to at least one tet operator sequence, introducing into the cell a second nucleic acid molecule encoding a tTA, to form a modified cell, administering the modified cell to the subject, and modulating the concentration of a tetracycline, or analogue thereof, in the subject. The first and second nucleic acid molecule can be within a single molecule (e.g.Type: GrantFiled: March 30, 1999Date of Patent: August 31, 2004Assignee: Abbott GmbH & Co., KGInventors: Hermann Bujard, Manfred Gossen, Jochen G. Salfeld, Jeffrey W. Voss
-
Patent number: 6780987Abstract: The invention provides isolated nucleic acids molecules, designated &bgr;CAP73 nucleic acid molecules, which encode a novel actin binding protein. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing &bgr;CAP73 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a &bgr;CAP73 gene has been introduced or disrupted. The invention still further provides isolated &bgr;CAP73 proteins, fusion proteins, mutant proteins, antigenic peptides and anti-&bgr;CAP73 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: December 28, 2000Date of Patent: August 24, 2004Assignee: Trustees of the Tufts CollegeInventors: Ira Herman, Alice Y. Welch
-
Patent number: 6777447Abstract: Benzylidene cyclohexanone, cyclopentanone and acteone derivatives and therapeutic methods of using same are disclosed. The compounds are non-toxic and exhibit potent anti-inflammatory, antibacterial and antioxidation activity. Also, certain compounds of the invention inhibit glutathione S-transferase (“GST”), but do not irritate the gastrointestinal tract. Pharmaceutical compositions containing the compounds of the invention and pharmaceutically acceptable carriers are also disclosed.Type: GrantFiled: February 27, 2002Date of Patent: August 17, 2004Inventors: Mochammad Samhoedi Reksohadiprodjo, Henk Timmerman, Sardjiman Dummy, Supardjan Amir Margono, Sudibyo Martono, Sugiyanto Dummy, Lukman Rahman Hakim, Nurlaila Dummy, Arief Rahman Hakim, Ika Puspitasari, Arief Nurrochmad, Purwantiningsih Dummy, Oetari Dummy, Tedjo Yuwono
-
Patent number: 6737039Abstract: Improved methods for detecting lesions in dense breast tissue are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist in an amount and for a period of time sufficient to reduce the density of breast tissue prior to generating an image of the breast tissue, for example by mammography, to detect a lesion in the breast tissue. Packaged formulations for reducing breast density in a subject prior to generating an image of the subject's breast tissue, comprising an LHRH antagonist packaged with instructions for using the LHRH antagonist to reduce breast density in a subject prior to imaging the breast tissue, are also disclosed.Type: GrantFiled: December 12, 2002Date of Patent: May 18, 2004Assignee: Praecis Pharmaceutics, Inc.Inventor: Marc B. Garnick
-
Patent number: 6726895Abstract: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described. Methods for tumor radiotherapy are also provided.Type: GrantFiled: April 3, 2002Date of Patent: April 27, 2004Assignees: Board of Trustees of the Leland Stanford Junior University, Theseus Imaging CorporationInventors: H. William Strauss, Francis G. Blankenberg, Allan M. Green, Neil Steinmetz
-
Patent number: 6713245Abstract: The instant methods pertain to an improved methods for storing neural cells, preferably dissociated neural cells, prior to their use in transplantation and to the cells obtained using such methods. One embodiment pertains to methods for storing the neural cells in medium lacking added buffer or added protein, other embodiments feature neural cells which are maintained at 4° C. prior to cryopreservation and have comparable viability and/or functionality to freshly harvested cells. In addition, methods for storing and/or transplantation of porcine neural cells are described.Type: GrantFiled: July 6, 1998Date of Patent: March 30, 2004Assignees: Diacrin, Inc., University Hospital GroningenInventors: Jan Koopmans, Douglas B. Jacoby, Jonathan Dinsmore
-
Patent number: 6703367Abstract: Methods to inhibit hot flashes or gynaecomastia in a subject are provided. In the methods of the invention, an LHRH antagonist is administered to a subject in need of treatment for hot flashes or gynaecomastia such that hot flashes or gynaecomastia are inhibited in the subject. In a particularly preferred embodiment, the invention provides a method for inhibiting menopause-related hot flashes in which an LHRH antagonist is administered to a subject in need of treatment for menopause-related hot flashes such that the hot flashes are inhibited in the subject.Type: GrantFiled: February 16, 2001Date of Patent: March 9, 2004Assignee: Praecis Pharmaceuticals Inc.Inventor: Marc B. Garnick
-
Patent number: 6703395Abstract: The present invention is based on the method of treating a patient suffering from leukemia comprising administering a therapeutically effective amount of the compound 2-([(3-hydroxypropyl)amino]-6-benzylamino)-9-isopropylpurine or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 23, 2001Date of Patent: March 9, 2004Assignee: Institute of Experimental Botany of the Academy of Sciences of the Czech RepublicInventors: Libor Havlicek, Miroslav Strnad, Marian Hajduch
-
Patent number: 6699854Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.Type: GrantFiled: December 20, 2002Date of Patent: March 2, 2004Assignee: Cyclacel LimitedInventors: Shudong Wang, Peter M. Fischer
-
Patent number: 6696561Abstract: Isolated nucleic acid molecules, designated MCT nucleic acid molecules, which encode novel MCT proteins from Corynebacterium glutamicum are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MCT nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated MCT proteins, mutated MCT proteins, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from C. glutamicum based on genetic engineering of MCT genes in this organism.Type: GrantFiled: June 23, 2000Date of Patent: February 24, 2004Assignee: BASF AktiengesellschaftInventors: Markus Pompejus, Burkhard Kröger, Hartwig Schröder, Oskar Zelder, Gregor Haberhauer
-
Patent number: 6689876Abstract: Isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, DNA encoding two major D. farinae allergens, Der f I and Der f II and DNA encoding a D. pteronyssinus allergen, Der p I. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.Type: GrantFiled: December 29, 1993Date of Patent: February 10, 2004Assignee: Immulogic Pharmaceutical CorporationInventors: Wayne Robert Thomas, Kaw-Yan Chua
-
Patent number: 6682928Abstract: Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.Type: GrantFiled: December 2, 1998Date of Patent: January 27, 2004Assignee: Medarex, Inc.Inventors: Tibor Keler, Joel Goldstein, Robert Graziano, Yashwant M. Deo
-
Patent number: 6632608Abstract: The invention demonstrates that the transcription factor XBP-1 is a regulator of hepatocyte growth, plasma cell differentiation and T cell subset activity. Methods for identifying modulators of hepatocyte growth, plasma cell differentiation and/or T cell subset activity, using XBP-1-containing indicator compositions or XBP-1-deficient cells, are provided. Methods of modulating hepatocyte growth, plasma cell differentiation and/or T cell subset activity (e.g., Th2 cytokine production) using agents that modulate the activity of XBP-1 are also provided. Methods for diagnosing disorders associated with aberrant hepatocyte growth, plasma cell differentiation and/or T cell subset activity, by assessing a change in XBP-1 expression, are also provided. XBP-1 deficient cells, animals and embryos, as well as kits for the methods of the invention, are also provided by the invention.Type: GrantFiled: December 29, 2000Date of Patent: October 14, 2003Assignee: President and Fellows of Harvard CollegeInventors: Laurie H. Glimcher, Andreas M. Reimold